Receptor, Fibroblast Growth Factor, Type 3
"Receptor, Fibroblast Growth Factor, Type 3" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A fibroblast growth factor receptor that regulates CHONDROCYTE growth and CELL DIFFERENTIATION. Mutations in the gene for fibroblast growth factor receptor 3 have been associated with ACHONDROPLASIA; THANATOPHORIC DYSPLASIA and NEOPLASTIC CELL TRANSFORMATION.
| Descriptor ID |
D051498
|
| MeSH Number(s) |
D08.811.913.696.620.682.725.400.179 D12.776.543.750.630.442 D12.776.543.750.750.400.370.875 D12.776.624.664.700.792
|
| Concept/Terms |
Receptor, Fibroblast Growth Factor, Type 3- Receptor, Fibroblast Growth Factor, Type 3
- FGFR3 Protein
- Receptor 3, Fibroblast Growth Factor
- Fibroblast Growth Factor Receptor 3
- CD333 Antigen
- Antigen, CD333
- Fibroblast Growth Factor Receptors 3
|
Below are MeSH descriptors whose meaning is more general than "Receptor, Fibroblast Growth Factor, Type 3".
- Chemicals and Drugs [D]
- Enzymes and Coenzymes [D08]
- Enzymes [D08.811]
- Transferases [D08.811.913]
- Phosphotransferases [D08.811.913.696]
- Phosphotransferases (Alcohol Group Acceptor) [D08.811.913.696.620]
- Protein Kinases [D08.811.913.696.620.682]
- Protein-Tyrosine Kinases [D08.811.913.696.620.682.725]
- Receptor Protein-Tyrosine Kinases [D08.811.913.696.620.682.725.400]
- Receptor, Fibroblast Growth Factor, Type 3 [D08.811.913.696.620.682.725.400.179]
- Amino Acids, Peptides, and Proteins [D12]
- Proteins [D12.776]
- Membrane Proteins [D12.776.543]
- Receptors, Cell Surface [D12.776.543.750]
- Receptor Protein-Tyrosine Kinases [D12.776.543.750.630]
- Receptor, Fibroblast Growth Factor, Type 3 [D12.776.543.750.630.442]
- Receptors, Peptide [D12.776.543.750.750]
- Receptors, Growth Factor [D12.776.543.750.750.400]
- Receptors, Fibroblast Growth Factor [D12.776.543.750.750.400.370]
- Receptor, Fibroblast Growth Factor, Type 3 [D12.776.543.750.750.400.370.875]
- Neoplasm Proteins [D12.776.624]
- Oncogene Proteins [D12.776.624.664]
- Proto-Oncogene Proteins [D12.776.624.664.700]
- Receptor, Fibroblast Growth Factor, Type 3 [D12.776.624.664.700.792]
Below are MeSH descriptors whose meaning is more specific than "Receptor, Fibroblast Growth Factor, Type 3".
This graph shows the total number of publications written about "Receptor, Fibroblast Growth Factor, Type 3" by people in this website by year, and whether "Receptor, Fibroblast Growth Factor, Type 3" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 |
| 2001 | 0 | 1 | 1 |
| 2005 | 0 | 1 | 1 |
| 2007 | 1 | 1 | 2 |
| 2009 | 0 | 1 | 1 |
| 2014 | 3 | 0 | 3 |
| 2016 | 1 | 1 | 2 |
| 2018 | 1 | 0 | 1 |
| 2019 | 1 | 0 | 1 |
| 2020 | 1 | 2 | 3 |
| 2024 | 1 | 2 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Receptor, Fibroblast Growth Factor, Type 3" by people in Profiles.
-
Rogaratinib Plus Atezolizumab in Cisplatin-Ineligible Patients With FGFR RNA-Overexpressing Urothelial Cancer: The FORT-2 Phase 1b Nonrandomized Clinical Trial. JAMA Oncol. 2024 Nov; 10(11):1565-1570.
-
Advances, recognition, and interpretation of molecular heterogeneity among conventional and subtype histology of urothelial carcinoma (UC): a survey among urologic pathologists and comprehensive review of the literature. Histopathology. 2024 Nov; 85(5):748-759.
-
Dysregulated FGFR3 signaling alters the immune landscape in bladder cancer and presents therapeutic possibilities in an agent-based model. Front Immunol. 2024; 15:1358019.
-
FGFR3 Alterations in the Era of Immunotherapy for Urothelial Bladder Cancer. Front Immunol. 2020; 11:575258.
-
Targetable gene fusions and aberrations in genitourinary oncology. Nat Rev Urol. 2020 11; 17(11):613-625.
-
Baseline Computed Tomography Radiomic and Genomic Assessment of Head and Neck Squamous Cell Carcinoma. J Comput Assist Tomogr. 2020 Jul/Aug; 44(4):546-552.
-
SWOG S1400D (NCT02965378), a Phase II Study of the Fibroblast Growth Factor Receptor Inhibitor AZD4547 in Previously Treated Patients With Fibroblast Growth Factor Pathway-Activated Stage IV Squamous Cell Lung Cancer (Lung-MAP Substudy). J Thorac Oncol. 2019 10; 14(10):1847-1852.
-
Novel phenotype of achondroplasia due to biallelic FGFR3 pathogenic variants. Am J Med Genet A. 2018 07; 176(7):1675-1679.
-
Pulmonary fibrosis requires cell-autonomous mesenchymal fibroblast growth factor (FGF) signaling. J Biol Chem. 2017 06 23; 292(25):10364-10378.
-
Spectrum of genomic alterations in FGFR3: current appraisal of the potential role of FGFR3 in advanced urothelial carcinoma. BJU Int. 2016 Nov; 118(5):681-691.